Activity of a Novel 1,3-Beta-D-Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata

被引：25
|
作者：
Ghannoum, M. [1 ,2 ]
Long, L. [1 ,2 ]
Isham, N. [1 ,2 ]
Hager, C. [1 ,2 ]
Wilson, R. [1 ,2 ]
Borroto-Esoda, K. [3 ]
Barat, S. [3 ]
Angulo, D. [3 ]
机构：
[1] Case Western Reserve Univ, Ctr Med Mycol, Cleveland, OH 44106 USA
[2] Univ Hosp Cleveland Med Ctr, Cleveland, OH 44106 USA
[3] Scynexis Inc, Jersey City, NJ USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2019年 / 63卷 / 12期
关键词：
Candida glabrata; fks mutation; ibrexafungerp; MK-3118;
D O I：
10.1128/AAC.01510-19
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Ibrexafungerp (formerly SCY-078), a novel glucan synthase inhibitor with oral availability, was evaluated for activity against Candida glabrata. The susceptibility of clinical strains to ibrexafungerp was determined by microdilution and time-kill assays. The MIC range against wild-type strains was 1 to 2 mu g/ml. Ibrexafungerp was also active against the majority of echinocandin-resistant strains. Time-kill studies showed 4- to 6-log-unit reductions in growth at 24 and 48 h with concentrations of 0.25 to 4 mu g/ml.
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-D-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis
    Petraitis, Vidmantas
    Petraitiene, Ruta
    Katragkou, Aspasia
    Maung, Bo Bo Win
    Naing, Ethan
    Kavaliauskas, Povilas
    Barat, Stephen
    Borroto-Esoda, Katyna
    Azie, Nkechi
    Angulo, David
    Walsh, Thomas J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (06)
  • [12] In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
    Quindos, Guillermo
    Miranda-Cadena, Katherine
    San-Millan, Rosario
    Borroto-Esoda, Katyna
    Canton, Emilia
    Linares-Sicilia, Maria Jose
    Hamprecht, Axel
    Montesinos, Isabel
    Tortorano, Anna Maria
    Prigitano, Anna
    Vidal-Garcia, Matxalen
    Marcos-Arias, Cristina
    Guridi, Andrea
    Sanchez-Reus, Ferran
    Machuca-Barcena, Jesus
    Rodriguez-Iglesias, Manuel Antonio
    Martin-Mazuelos, Estrella
    Castro-Mendez, Carmen
    Lopez-Soria, Leyre
    Ruiz-Gaitan, Alba
    Fernandez-Rivero, Marcelo
    Lorenzo, Damaris
    Capilla, Javier
    Rezusta, Antonio
    Peman, Javier
    Guarro, Josep
    Pereira, Joana
    Pais, Celia
    Romeo, Orazio
    Ezpeleta, Guillermo
    Jauregizar, Nerea
    Angulo, David
    Eraso, Elena
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [13] SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against Candida, Aspergillus and Pneumocystis spp.
    Barat, Stephen
    Borroto-Esoda, Katyna
    Angulo, David
    MEDICAL MYCOLOGY, 2018, 56 : S44 - S44
  • [14] ECHINOCANDIN INHIBITION OF 1,3-BETA-D-GLUCAN SYNTHASE FROM CANDIDA-ALBICANS
    SAWISTOWSKASCHRODER, ET
    KERRIDGE, D
    PERRY, H
    FEBS LETTERS, 1984, 173 (01) : 134 - 138
  • [15] In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents
    Arendrup, Maiken Cavling
    Jorgensen, Karin Meinike
    Hare, Rasmus Kroger
    Chowdhary, Anuradha
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [16] Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors.
    Okada, T
    Masubuchi, K
    Kohchi, M
    Murata, T
    Kondoh, O
    Yamazaki, T
    Kobayashi, K
    Inoue, T
    Horii, I
    Shimma, N
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : A118 - A118
  • [17] The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation
    Larkin, Emily
    Hager, Christopher
    Chandra, Jyotsna
    Mukherjee, Pranab K.
    Retuerto, Mauricio
    Salem, Iman
    Long, Lisa
    Isham, Nancy
    Kovanda, Laura
    Borroto-Esoda, Katyna
    Wring, Steve
    Angulo, David
    Ghannoum, Mahmoud
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (05)
  • [18] Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model
    Lepak, Alexander J.
    Marchillo, Karen
    Andes, David R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (02) : 1265 - 1272
  • [19] Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors
    Douglas, CM
    DIppolito, JA
    Shei, GJ
    Meinz, M
    Onishi, J
    Marrinan, JA
    Li, W
    Abruzzo, GK
    Flattery, A
    Bartizal, K
    Mitchell, A
    Kurtz, MB
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) : 2471 - 2479
  • [20] PHOSPHATASES AND PHOSPHODIESTERASES INTERFERE WITH 1,3-BETA-D-GLUCAN SYNTHASE ACTIVITY IN PEA EPICOTYL MEMBRANE PREPARATIONS
    SAUGY, M
    FARKAS, V
    MACLACHLAN, G
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 177 (01): : 135 - 138
12345